JP2004533445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533445A5 JP2004533445A5 JP2002588988A JP2002588988A JP2004533445A5 JP 2004533445 A5 JP2004533445 A5 JP 2004533445A5 JP 2002588988 A JP2002588988 A JP 2002588988A JP 2002588988 A JP2002588988 A JP 2002588988A JP 2004533445 A5 JP2004533445 A5 JP 2004533445A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- mammal
- disorder
- day
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 241000124008 Mammalia Species 0.000 claims 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 14
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims 12
- 208000007656 osteochondritis dissecans Diseases 0.000 claims 12
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 8
- 206010034158 Pathological gambling Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000001575 pathological effect Effects 0.000 claims 5
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 208000032841 Bulimia Diseases 0.000 claims 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims 4
- 208000001836 Firesetting Behavior Diseases 0.000 claims 4
- 208000030990 Impulse-control disease Diseases 0.000 claims 4
- 208000028017 Psychotic disease Diseases 0.000 claims 4
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 4
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 4
- 229960004047 acamprosate Drugs 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- 208000022266 body dysmorphic disease Diseases 0.000 claims 4
- ZGLIFVFRIOKQLE-LVZFUZTISA-N chembl2104573 Chemical compound C=1C(Cl)=CC=C(O)C=1C(=N/CCCC)/C1=CC=CC=C1Cl ZGLIFVFRIOKQLE-LVZFUZTISA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- 229950004395 fengabine Drugs 0.000 claims 4
- 229960002870 gabapentin Drugs 0.000 claims 4
- 230000003370 grooming effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229960004394 topiramate Drugs 0.000 claims 4
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 4
- 229960000604 valproic acid Drugs 0.000 claims 4
- 206010036790 Productive cough Diseases 0.000 claims 3
- IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 claims 3
- 229960002752 progabide Drugs 0.000 claims 3
- 210000003802 sputum Anatomy 0.000 claims 3
- 208000024794 sputum Diseases 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- FQZPXSRKCOWUEI-UHFFFAOYSA-N hexadecyl 4-aminobutanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCN FQZPXSRKCOWUEI-UHFFFAOYSA-N 0.000 claims 2
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims 2
- 229960001918 tiagabine Drugs 0.000 claims 2
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims 2
- 208000001613 Gambling Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/853,392 US6462084B1 (en) | 2001-05-14 | 2001-05-14 | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
| PCT/US2002/014344 WO2002092071A1 (en) | 2001-05-14 | 2002-05-08 | Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004533445A JP2004533445A (ja) | 2004-11-04 |
| JP2004533445A5 true JP2004533445A5 (enExample) | 2005-12-22 |
Family
ID=25315916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002588988A Pending JP2004533445A (ja) | 2001-05-14 | 2002-05-08 | Ｇｖｇを用いた強迫障害（ｏｃｄ）及びｏｃｄ−関連障害の新規治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6462084B1 (enExample) |
| EP (1) | EP1392273A4 (enExample) |
| JP (1) | JP2004533445A (enExample) |
| KR (1) | KR20040028758A (enExample) |
| CN (1) | CN1509168A (enExample) |
| BR (1) | BR0209614A (enExample) |
| CA (1) | CA2446641A1 (enExample) |
| CZ (1) | CZ20033379A3 (enExample) |
| HR (1) | HRP20030894A2 (enExample) |
| HU (1) | HUP0400032A3 (enExample) |
| IL (1) | IL158761A0 (enExample) |
| MX (1) | MXPA03010406A (enExample) |
| NO (1) | NO20035037L (enExample) |
| NZ (1) | NZ529613A (enExample) |
| PL (1) | PL367362A1 (enExample) |
| TW (1) | TWI313599B (enExample) |
| WO (1) | WO2002092071A1 (enExample) |
| YU (1) | YU89103A (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002227052A1 (en) | 2000-11-30 | 2002-06-11 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
| JP2005534678A (ja) * | 2002-06-27 | 2005-11-17 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 注意欠陥多動性障害の治療方法 |
| US7393537B2 (en) | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
| WO2004096269A2 (en) * | 2003-04-25 | 2004-11-11 | Allergan, Inc. | Botulinum neurotoxin for treating tics and obsessive compulsive behaviors |
| US20110275664A1 (en) * | 2005-09-26 | 2011-11-10 | The Regents Of The University Of Colorado,A Body Corporate | Method for treating drug and behavioral addictions |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| AU2012345659B2 (en) | 2011-12-02 | 2017-09-28 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| WO2014197744A1 (en) * | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| CN104306736A (zh) * | 2014-10-31 | 2015-01-28 | 哈尔滨市海江科技开发有限公司 | 一种治疗疑病症的膏药及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4761429A (en) | 1985-07-22 | 1988-08-02 | Kenneth Blum | Enkephalinase and endorphinase inhibitors as anti-craving compositions |
| US5189064A (en) | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
| US4786647A (en) | 1986-06-30 | 1988-11-22 | University Of Florida | Method for eliciting anxiolysis |
| US4980168A (en) | 1989-10-13 | 1990-12-25 | Natrol, Inc. | Dietary supplement for children |
| EP0767174A1 (de) | 1991-11-21 | 1997-04-09 | Ciba-Geigy Ag | Neue Aminoalkanphosphinsäuren und ihre Salze |
| DK0641330T3 (da) * | 1992-05-20 | 2001-12-03 | Univ Northwestern | Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling |
| US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| EP0915697B1 (en) | 1996-06-28 | 2002-09-18 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
| US5776956A (en) | 1996-07-30 | 1998-07-07 | Lectec Corporation | Use of cotinine in treating psychiatric disorders |
| US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| IL135659A0 (en) | 1997-10-28 | 2001-05-20 | Schering Corp | Method of reducing craving in mammals |
| US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| MXPA01004015A (es) * | 1998-10-20 | 2003-03-10 | Johnson & Johnson | Derivados anticonvulsivos utiles para el tratamiento de la dependencia, adiccion y abuso del alcohol. |
| MXPA01007758A (es) | 1999-02-01 | 2003-06-24 | Johnson & Johnson | Uso de derivados de anticonvulsivos para tratar la bulimia nerviosa. |
| NZ513643A (en) | 1999-02-24 | 2005-04-29 | Univ Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
| AU4050100A (en) | 1999-04-08 | 2000-11-14 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in maintaining weight loss |
| AU2002227052A1 (en) * | 2000-11-30 | 2002-06-11 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
-
2001
- 2001-05-14 US US09/853,392 patent/US6462084B1/en not_active Expired - Fee Related
-
2002
- 2002-05-08 HU HU0400032A patent/HUP0400032A3/hu unknown
- 2002-05-08 BR BR0209614-5A patent/BR0209614A/pt not_active IP Right Cessation
- 2002-05-08 JP JP2002588988A patent/JP2004533445A/ja active Pending
- 2002-05-08 PL PL02367362A patent/PL367362A1/xx not_active Application Discontinuation
- 2002-05-08 NZ NZ529613A patent/NZ529613A/en unknown
- 2002-05-08 IL IL15876102A patent/IL158761A0/xx unknown
- 2002-05-08 CA CA002446641A patent/CA2446641A1/en not_active Abandoned
- 2002-05-08 KR KR10-2003-7014792A patent/KR20040028758A/ko not_active Withdrawn
- 2002-05-08 YU YU89103A patent/YU89103A/sh unknown
- 2002-05-08 HR HR20030894A patent/HRP20030894A2/hr not_active Application Discontinuation
- 2002-05-08 CZ CZ20033379A patent/CZ20033379A3/cs unknown
- 2002-05-08 EP EP02729142A patent/EP1392273A4/en not_active Withdrawn
- 2002-05-08 MX MXPA03010406A patent/MXPA03010406A/es active IP Right Grant
- 2002-05-08 CN CNA028098269A patent/CN1509168A/zh active Pending
- 2002-05-08 WO PCT/US2002/014344 patent/WO2002092071A1/en not_active Ceased
- 2002-05-13 TW TW091109922A patent/TWI313599B/zh not_active IP Right Cessation
- 2002-06-20 US US10/175,576 patent/US20020169103A1/en not_active Abandoned
-
2003
- 2003-11-13 NO NO20035037A patent/NO20035037L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Citraro et al. | Effects of histone deacetylase inhibitors on the development of epilepsy and psychiatric comorbidity in WAG/Rij rats | |
| Löscher | Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action | |
| Branchi et al. | Nonmotor symptoms in Parkinson's disease: Investigating early‐phase onset of behavioral dysfunction in the 6‐hydroxydopamine‐lesioned rat model | |
| Kuo et al. | Molecular pathology and pharmacological treatment of autism spectrum disorder-like phenotypes using rodent models | |
| Chen et al. | The roles of GABA in ischemia‐reperfusion injury in the central nervous system and peripheral organs | |
| Williams et al. | Nerve growth factor in treatment and pathogenesis of Alzheimer's disease | |
| Glajch et al. | Epigenetic mechanisms involved in Huntington's disease pathogenesis | |
| JP2016199576A5 (enExample) | ||
| FR2771004A1 (fr) | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse | |
| JP2012505238A5 (enExample) | ||
| Gladkova et al. | Epidrugs in the therapy of central nervous system disorders: a way to drive on? | |
| DK1678172T3 (da) | Azabicykliske forbindelser til lindring af smerte og behandling af sygdomme i centralnervesystemet | |
| WO2001078704A3 (en) | Gaba substrate and the use thereof for treating cognitive and emotional disorders | |
| BRPI0509908A (pt) | bioconversão estereosseletiva de dinitrilas alifáticas em ácidos cianocarboxìlicos | |
| WO2008030830A3 (en) | Sustained-release composition and method of use thereof | |
| Tapia-Rojas et al. | Ethanol Consumption Affects Neuronal Function: Role | |
| US6462084B1 (en) | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG | |
| RU2006143659A (ru) | Применение ребоксетина для лечения боли | |
| IL198891A0 (en) | Combination therapy of lower urinary tract disorders with ??2 ?? ligands and nsaids | |
| HRP20230745T3 (hr) | Spojevi morfina | |
| Wei et al. | Polysaccharide Engineered Nanozymes Target Inflammation for Alleviating Colitis‐Associated Mental Disorders via Microbiome‐Gut–Brain Axis | |
| Castro et al. | Chiral inversion of R (−) fenoprofen and ketoprofen enantiomers in cats | |
| FR2970711A1 (fr) | La lauflumide et ses enantiomeres, preparation et utilisations therapeutiques | |
| Zhu et al. | Combination administration of alprazolam and N-Ethylmaleimide synergistically enhances sleep behaviors in mice with no potential CNS side effects | |
| Dringenberg et al. | Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence |